


PRODUCT INFORMATION



17-DMAG

Item No. 11036

CAS Registry No.: 467214-20-6
Formal Name: 17-demethoxy-17-[[2-(dimethylamino)ethyl]amino]-geldanamycin
Synonyms: Alveuspimycin, KOS-1022, NSC 707545
MF: C₃₂H₄₈N₄O₈
FW: 616.8
Purity: ≥98%
UV/Vis.: λ_{max}: 220, 332, 529 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

17-DMAG is supplied as a crystalline solid. A stock solution may be made by dissolving the 17-DMAG in the solvent of choice. 17-DMAG is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of 17-DMAG in these solvents is approximately 2, 13, and 20 mg/ml, respectively.

17-DMAG is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, 17-DMAG should first be dissolved in DMF and then diluted with the aqueous buffer of choice. 17-DMAG has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Geldanamycin (Item No. 13355) is a potent inhibitor of Hsp90 that has poor water solubility. 17-DMAG is a water-soluble derivative of geldanamycin which potently inhibits Hsp90 (IC₅₀ = 24 nM) and has excellent bioavailability and tissue distribution in animals.¹ Like other Hsp90 inhibitors, 17-DMAG has diverse anti-tumor actions and has potential in treating certain types of cancer.²⁻⁶ This compound also suppresses inflammation by interfering with signaling through the NF-κB pathway.^{7,8} 17-DMAG also ameliorates high fat diet-induced renal failure in a mouse model of diabetes.⁹

References

1. Egorin, M.J., Lagattuta, T.F., Hamburger, D.R., et al. *Cancer Chemother. Pharmacol.* **49(1)**, 7-19 (2002).
2. Bull, E.E.A., Dote, H., Brady, K.J., et al. *Clin. Cancer Res.* **10(23)**, 8077-8084 (2004).
3. Taldone, T., Sun, W., and Chiosis, G. *Bioorg. Med. Chem.* **17(6)**, 2225-2235 (2009).
4. Hackl, C., Lang, S.A., Moser, C., et al. *BMC Cancer* **10(668)**, 1-9 (2010).
5. Ramanathan, R.K., Egorin, M.J., Erlichman, C., et al. *J. Clin. Oncol.* **28(9)**, 1520-1526 (2010).
6. Kobayashi, N., Toyooka, S., Soh, J., et al. *Lung Cancer* **75(2)**, 161-166 (2012).
7. Madrigal-Matute, J., López-Franco, O., Blanco-Colio, L.M., et al. *Cardiovasc. Res.* **86(2)**, 330-337 (2010).
8. Shimp, S.K.I., Parson, C.D., Regna, N.L., et al. *Inflamm. Res.* **61(5)**, 521-533 (2012).
9. Zhang, H.-M., Dang, H., Kamat, A., et al. *PLoS One* **7(3)**, 1-9 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/28/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM